GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2006

Alkermes and RPI Partner to Develop Opioid Receptor Compounds

  • Rensselaer Polytechnic Institute granted Alkermes exclusive rights to certain patents and patent applications relating to its compounds designed to modulate opioid receptors.

    These compounds represent an opportunity for Alkermes to develop therapeutics for a broad range of diseases and medical conditions, including addiction, pain, and other central nervous system disorders. Alkermes will screen this library of compounds and plans to pursue preclinical work of an undisclosed lead oral compound that has already been identified.

    Alkermes will be responsible for the continued R&D of any resulting product candidates. Rensselaer will receive from Alkermes an upfront payment, certain milestone payments relating to clinical development activities, and royalties on products resulting from the agreement.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?